Oda, S.; Kawakubo, K.; Kuwatani, M.; Tanaka, S.; Nakajima, K.; Shiratori, S.; Yonemura, H.; Nozawa, S.; Hirata, K.; Sugiura, R.;
et al. DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. Cancers 2025, 17, 3936.
https://doi.org/10.3390/cancers17243936
AMA Style
Oda S, Kawakubo K, Kuwatani M, Tanaka S, Nakajima K, Shiratori S, Yonemura H, Nozawa S, Hirata K, Sugiura R,
et al. DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. Cancers. 2025; 17(24):3936.
https://doi.org/10.3390/cancers17243936
Chicago/Turabian Style
Oda, Soichiro, Kazumichi Kawakubo, Masaki Kuwatani, Shugo Tanaka, Katsuma Nakajima, Shoya Shiratori, Hiroki Yonemura, Shunichiro Nozawa, Koji Hirata, Ryo Sugiura,
and et al. 2025. "DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment" Cancers 17, no. 24: 3936.
https://doi.org/10.3390/cancers17243936
APA Style
Oda, S., Kawakubo, K., Kuwatani, M., Tanaka, S., Nakajima, K., Shiratori, S., Yonemura, H., Nozawa, S., Hirata, K., Sugiura, R., & Sakamoto, N.
(2025). DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. Cancers, 17(24), 3936.
https://doi.org/10.3390/cancers17243936
